Sassy,1) If the selling price exceeds the costs (production &...

Sassy,

1) If the selling price exceeds the costs (production & royalties), GSK will pocket the difference as profit – is this not a benefit?

2) GSK has contractual obligations to BTA to market at best efforts to the territories that were granted to GSK in the licensing agreement which included China.

The idiot Peter Cook is praising GSK to justify his idiotic legal settlement. Rumours have it that the idiot is rewarded with hundreds of thousands of free options as if he Peter Idiot single handedly increased Relenza sales.

Will the Chinese market and sub-license bring money to BTA shareholders? Read this 2009 article:
http://www.chinadaily.com.cn/bizchina/2009-02/06/content_7450505.htm

Quote: "Test procedures for the drug Zanamivir are still being decided. It would take a long time to complete the clinical trials," said Xu Xiaoping, a member of the institute.

So why is GSK’s best effort in manufacturing and sub-licensing so pathetic? Read this if you want to know the answer:

http://www.hotcopper.com.au/post_single.asp?fid=1&tid=945753&msgid=5270583